Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and ...

Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertiseZURICH, ...

Cartherics and Zucker Institute execute research collaboration and option agreement to combine iPSC-derived NK cell ...

Spider-Man: Brand New Day science advanced in real time during the film's run: a 2025 Wellesley College study challenged the ...

Berserk of Gluttony Season 2 is confirmed for 2027: Point Set announced the broadcast window on August 23, with voice ...

Natera and Angiex partner to assess response to investigational Nuclear-Delivered Antibody-Drug Conjugate using Signatera: Austin, Texas Saturday, August 29, 2026, 14:00 Hrs [IST] ...

Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational ...

Experts from Lonza discuss how advances in ADCs, dual-payload designs, RNA delivery, and bioconjugates are expanding targeted ...

Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global ...

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in ...

Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare ...

According to MarketsandMarkets™, the Oligonucleotide CDMO Market is projected to reach USD 11.14 billion by 2031 from USD ...